Loading
When lutetium radioligand therapy stops working, alpha-emitting versions can still control the disease.
This sequence moves from beta-emitting lutetium-177 dotatate to an alpha-emitting radioligand, 212Pb-DOTAMTATE, when beta PRRT stops controlling a neuroendocrine tumour. Alpha particles deliver oxygen-independent clustered DNA damage that beta-resistant clones cannot repair, so the same somatostatin receptor target can be attacked again with a more destructive payload. The phase 2 ALPHAMEDIX-02 trial included a PRRT-exposed cohort in which disease control was maintained in most patients, and ACTION-1 is the randomised phase 3 test of 225Ac-DOTATATE after 177Lu. The pairing belongs to the wider topic of alpha versus beta emitters and targeted alpha therapy.
Shares ALPHAMEDIX-02, 212Pb-DOTAMTATE, Targeted alpha therapy, Neuroendocrine tumours.
Shares Alpha vs beta emitters, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
Shares ALPHAMEDIX-02, 212Pb-DOTAMTATE, Targeted alpha therapy, Neuroendocrine tumours.
Shares Alpha vs beta emitters, Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.
Shares Alpha vs beta emitters, Targeted alpha therapy, Neuroendocrine tumours.
Shares Lutetium-177 dotatate, Targeted alpha therapy, Neuroendocrine tumours.